A first-in-human Phase I dose-escalation trial of the novel therapeutic peptide, ALM201, demonstrates a favourable safety profile in unselected patients with ovarian cancer and other advanced solid tumours.
Aya El HelaliRuth PlummerGordon C JaysonVicky M CoyleYvette DrewNerissa MescalladoNoor HarrisAndrew R ClampJanine McCannHelen SwaislandRichard D KennedyAaron N CranstonRichard H WilsonPublished in: British journal of cancer (2022)
Doses up to 300 mg of ALM201 subcutaneously are feasible and well-tolerated. Further investigation of this agent in selected tumour types/settings would benefit from patient-selection biomarkers.